The ongoing policy debate about pharmaceutical and biologic patents has been coopted by those who don’t like patents—including those who have a financial incentive not to like patents. These paid mercenaries concoct and then disseminate fraudulent “reports”, which have become the lifeblood for patent critics. Even when the inaccuracies and lies are clearly identified, the cacophony of patent haters drowns out the truth thanks to a complicit, ideologically aligned popular press that continues to cite and rely on fabricated “findings” that couldn’t stand up to the scrutiny of your average fifth grader.
The post Amgen Attacks Academics’ False Claims About Biologic Patents appeared first on IPWatchdog.com | Patents & Intellectual Property Law.
Recent Posts
- Amgen Attacks Academics’ False Claims About Biologic Patents
- Other Barks & Bites for Friday, September 19: John Squires Confirmed as USPTO Director; Divided Fifth Circuit Affirms Injunction on Noncompete Clauses; EPO Reports Threefold Increase in Digital Agriculture Tech Since 2000
- Squires Confirmed to USPTO: Recapping His Statements So Far on Plans for the Office
- Squires Likely to Be Confirmed as USPTO Director Thursday via Nuclear Option for Trump Nominees
- IP as a Force for Good: A Conversation with WIPO Director General Daren Tang